Study Overview - Clinical Trial Results .org

More documents

Recommendations

Info

Primary OutcomeStroke (ischemic or hemorrhagic) or systemic embolismP (non-inferiority)
EfficacyJapan vs. GlobalEfficacy Outcome (ITT)JapanGlobalEvent Rate (%/yr)Apixaban WarfarinEvent Rate (%/yr)Apixaban Warfarin HR (95% CI)N=161 N=175 N=9120 N=9081P ValueStroke or systemic embolism 0.87 1.67 1.27 1.60 0.79 (0.66, 0.95) 0.011Stroke 0.87 1.67 1.19 1.51 0.79 (0.65, 0.95) 0.012Ischemic or uncertain 0.87 1.11 0.97 1.05 0.92 (0.74, 1.13) 0.42Hemorrhagic 0 0.55 0.24 0.47 0.51 (0.35, 0.75) < 0.001Systemic embolism (SE) 0 0 0.09 0.10 0.87 (0.44, 1.75) 0.70All-cause death 1.74 3.02 3.52 3.94 0.89 (0.80, 0.998) 0.047Stroke, SE, or all-cause death 2.62 3.90 4.49 5.04 0.89 (0.81, 0.98) 0.019MI 0 0.28 0.53 0.61 0.88 (0.66, 1.17) 0.37
Page 2 and 3: 1 Consultation fees:EISAI2 Stock ow
Page 4: Atrial Fibrillation with at Least O
Page 7: Baseline CharacteristicsCharacteris
Page 11 and 12: BleedingJapan vs. GlobalOutcomePrim
Page 13 and 14: Adverse Events and Liver Function T
Page 15: THANKS to all Japan CollaboratorsNa

Study Overview - Clinical Trial Results .org

Create successful ePaper yourself

Delete template?

Save as template?